Henric Roth | People | Baker McKenzie

Biography

Henric Roth is based in Stockholm and a partner in the Capital Markets team. He joined Baker McKenzie in 2010. Mr. Roth graduated from Lund University (LL.M., jur. kand.) in 2010 and has also studied at the University of California, Santa Barbara in 2008/2009. Further, he has taken several classes in Business Administration and Economics at the University of Lund and has experience working as an officer in the reserve for the Swedish Navy. Mr. Roth was seconded to the Firm’s London Office for six months in 2016/2017. In 2018/2019 he was seconded as in-house legal counsel to one of the leading investment banks in the Nordics. During the last four years (2016-2019), Baker McKenzie's Capital Markets Group in Stockholm has been ranked #1 in acting for investment banks in capital markets transactions (in terms of deal volume) and #1-3 in acting for issuers in capital markets transactions (in terms of deal volume).

Practice Focus

Mr. Roth specializes in capital markets work, representing late-stage private and publicly traded companies, sponsors and underwriters, with a particular emphasis on capital markets transactions within two of the most rapidly growing industries: technology and life sciences. He has extensive experience counseling clients on the full range of capital markets related matters, including IPOs, public offerings, secondary share issues, public mergers and acquisitions, strategic corporate relationships, compliance and corporate governance.

Representative Legal Matters

Lead partner in acting for Citi, Carnegie, Nordea, BNP Paribas and Danske Bank in connection with Asker Healthcare’s IPO on Nasdaq Stockholm.
Acted for Carnegie Investment Bank, Bryan Garnier and ABG Sundal Collier in Cinclus Pharma’s IPO on Nasdaq Stockholm.
Lead partner in acting for Citi, Carnegie, DNB Markets, Danske Bank and SEB in connection with Norva24’s IPO on Nasdaq Stockholm.
Lead partner in acting for Truecaller in its IPO on Nasdaq Stockholm.
Lead partner in acting for Olink in its USD 3.1 billion US public takeover by Thermo Fisher Scientific.
Lead partner in acting for Citi, Jefferies, Stifel and Carnegie in the Swedish issuer Calliditas Therapeutics' IPO on the Nasdaq Global Select Market in the United States.
Lead partner in acting for the minority selling shareholders in the IPO of Olink Holding AB on the Nasdaq Global Market in the United States.
Acted for FSN Capital and BHG in connection with its IPO on Nasdaq Stockholm.
Lead partner in acting for Carnegie, Citi, Morgan Stanley and Swedbank in the follow-on offering of shares in NENT Group (Viaplay).
Acted for DNB Carnegie and DNB Markets in connection with Bioarctic's IPO on Nasdaq Stockholm.

Professional Associations and Memberships

Swedish Bar Association - Member

Admissions

Sweden (2010)

Education

University of Lund, Sweden (Juris Kandidat (LL.M.)) (2010)
University of California at Santa Barbara (2009)
University of Lund, Sweden (Economics and Business Administration)

Languages

English
Swedish